Are novel drugs more risky for patients than less novel drugs?

Journal of Health Economics

Volumn 23, Issue 6, 2004, Pages 1135-1158

  Olson, Mary K ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

Drug novelty; Drug safety; FDA; New drug approvals; Pharmaceutical regulation

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; ORPHAN DRUG; TROGLITAZONE;

DRUG PRESCRIBING;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGY; ARTHRITIS; ASTHMA; BACTERIAL INFECTION; CANCER; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DEATH; DIABETES MELLITUS; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG QUALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; EPILEPSY; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HEALTH PRACTITIONER; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; INTERMETHOD COMPARISON; LIVER FAILURE; MALE; MATHEMATICAL MODEL; MEDICAL INFORMATION; PAIN; PATIENT; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STATISTICAL MODEL;

EID: 8844256592     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2004.03.007     Document Type: Article

References (24)

1. C. Baum, S.L. Kweder, and C. Anello The spontaneous reporting system in the United States B. Strom Pharmacoepidemiology second ed. 1994 John Wiley & Sons New York 125 155
2. A.C. Cameron, and P.K. Trivedi Regression Analysis of Count Data 1998 Cambridge University Press Cambridge
3. J.L. Carson, B.L. Strom, and G. Maislin Screening for unknown effects of newly marketed drugs B. Strom Pharmacoepidemiology second ed. 1994 John Wiley & Sons New York 1431 1467
4. Center for Drug Evaluation and Research, Food and Drug Administration, 1996a. Priority Review Policy, in the Manual of Policies and Procedures. MAPP 6020.3. Available at http://www.fda.gov/cder/mapp/6020-3.pdf.
5. Center for Drug Evaluation and Research, Food and Drug Administration, 1996b. The Clinical Impact of Adverse Event Reporting. A MedWatch continuing education article, October.
6. J. Cross, H. Lee, A. Westelinck, J. Nelson, C. Grudzinskas, and C. Peck Post-marketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999 Pharmacoepidemiology and Drug Safety 11 2002 439 446
7. D. Dranove, and D. Meltzer Do important drugs reach the market sooner? Rand Journal of Economics 25 1994 402 423
8. S. Epstein Impure Science: AIDS, Activism, and the Politics of Knowledge 1996 University of California Press Berkeley
9. H. Grabowski, and J. Vernon The Regulation of Pharmaceuticals: Balancing the Benefits and the Risks 1983 American Enterprise Institute Washington, DC
10. D. Graham, L. Green, J. Senior, and P. Nourjah Troglitazone-induced liver failure: a case study The American Journal of Medicine 114 2003 299 306
11. K.I. Kaitin, and M. Manocchia The new-drug approvals of 1993, 1994, and 1995: trends in drug development American Journal of Therapeutics 4 1 1997 46 54
12. K.I. Kaitin, M. Manocchia, M. Seibring, and L. Lasagna The new-drug approvals of 1990, 1991, and 1992: trends in drug development The Journal of Clinical Pharmacology 34 1994 120 127
13. K.I. Kaitin, N. Phelan, D. Raiford, and B. Morris Therapeutic ratings and end-of-phase II conferences: initiatives to accelerate the availability of important new drugs The Journal of Clinical Pharmacology 31 1 1991 17 24
14. D.A. Kessler Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems Journal of the American Medical Association 269 21 1993 2765 2768
15. K.E. Lasser, P.D. Allen, S.J. Woolhandler, D.U. Himmelstein, S.M. Wolfe, and D.H. Bor Timing of new black box warnings and withdrawals for prescription medications Journal of the American Medical Association 287 17 2002 2215 2220
16. F.R. Lichtenberg Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS Health Affairs 20 5 2001 241 251
17. F.R. Lichtenberg C. Corrado J. Haltiwanger D. Sichel Pharmaceutical Knowledge - Capital Accumulation and Longevity, in Measuring Capital in the New Economy 2002 University of Chicago Press Chicago
18. M.K. Olson Regulatory agency discretion among competing industries: inside the FDA Journal of Law, Economics & Organization 11 2 1995 379 405
19. M.K. Olson Pharmaceutical policy and the safety of new drugs Journal of Law and Economics 45 2 2002 615 642
20. M.K. Olson Managing delegation in the FDA: reducing delay in new-drug review Journal of Health Politics, Policy and Law 29 3 2004 397 430
21. Quirk, P.J., 1980. The food and drug administration. In: Wilson, J.Q. (Ed.), The Politics of Regulation. Basic Books.
22. Sasich, L., Lurie, P., Wolfe, S.M., 2000. The Drug Industry's Performance In Finishing Post-marketing Research (Phase IV) Studies. A Public Citizen's Health Research Group Report, No. 1520, Accessed at: http://www.publiccitizen. org/publications/.
23. S. Schweitzer Pharmaceutical Economics and Policy 1997 Oxford University Press New York
24. B.L. Strom Pharmacoepidemiology second ed. 1994 John Wiley & Sons New York